Clinical Trials Logo

Gastrointestinal Neoplasms clinical trials

View clinical trials related to Gastrointestinal Neoplasms.

Filter by:

NCT ID: NCT06018246 Completed - Clinical trials for Gastrointestinal Cancer

Nutritional Risk Screening Nutritional Support Gastrointestinal Cancer

Start date: July 20, 2021
Phase: N/A
Study type: Interventional

The goal of this clinical trial was to compare the effects of different nutritional support methods based on nutritional risk screening on postoperative nutritional status in patients with gastrointestinal tumors.The main question it aims to answer is that different types of nutrition can improve the nutritional status of patients with different nutritional status;Long-term dietary interventions for patients with poor nutrition can make cancer patients better able to tolerate surgery and chemotherapy and improve their quality of life.The intervention group received nutrition + exercise + psychological intervention upon admission, routine parenteral and enteral nutrition support after operation, and continued nutrition + exercise + psychological intervention after discharge.The control group received routine parenteral nutrition support in the department after surgery, and the patients and their families were given diet education during hospitalization.

NCT ID: NCT06017661 Recruiting - Immunomodulation Clinical Trials

Investigation of a Polyphenol-rich Preparation as Support for Oncology Patients Undergoing Gastrointestinal Tumor Resection

Start date: September 1, 2023
Phase: N/A
Study type: Interventional

The aim of the study is to demonstrate, under clinical conditions, the effectiveness of the standard product 'Nutridrink' enriched with a mixture of plant extracts rich in polyphenolic compounds in the aspect of supporting the recovery of oncology patients undergoing surgical resection of tumours.

NCT ID: NCT06015971 Recruiting - Sarcopenia Clinical Trials

Omega-3 Fatty Acids and Nutritional Support in Gastrointestinal Cancer

Start date: July 1, 2023
Phase: N/A
Study type: Interventional

Sarcopenia is a frequent complication in patients with cancer and chronic diseases, it is characterized by decreased muscle strength and fatigue due to reduced skeletal muscle mass, which is accompanied by atrophy and decreased quality of muscle tissue. In all cases, it negatively impacts treatment tolerance, clinical outcomes and survival, in consequence, quality of life of these patients decreases while morbidity, mortality and costs increase. In this context, appropriate nutritional screening and early nutrition support are extremely recommended, to this aim, in some cases, oral nutritional supplements (ONS) are necessary; ONS could have a standard formula or be enriched with specific nutrients (arginine, glutamine, branched chain amino acids, n-3 fatty acids, and nucleotides), which can modulate the activity of the immune system and provide an additional benefit beyond the nutritional support, this intervention type is called immunonutrition. Despite these possible benefits, their utility has been proven in few clinical scenarios, for example in with patients with upper gastrointestinal cancer undergoing surgical resection; based on this, current guidelines recommend that patients should receive oral/enteral nutritional support with an specific formula enriched in immunonutrients (with arginine, n-3 fatty acids or nucleotides) , but there is a lack of evidence for supporting its use in other clinical conditions including patients with cancer that receive systemic treatment

NCT ID: NCT06008054 Recruiting - Colorectal Cancer Clinical Trials

A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Esophageal Cancer, Gastric Cancer, Colorectal Cancer and Other Gastrointestinal Tumors

Start date: November 16, 2023
Phase: Phase 2
Study type: Interventional

Objective: To investigate the efficacy, safety and tolerability of SI-B003 monotherapy and BL-B01D1+SI-B003 dual agents in patients with locally advanced or metastatic esophageal cancer, gastric cancer, colorectal cancer and other gastrointestinal tumors, and to further explore the optimal dose and mode of combination.

NCT ID: NCT06002425 Recruiting - Clinical trials for Gastrointestinal Neoplasm Malignant

Treatment Recommendations for Gastrointestinal Cancers Via Large Language Models

Start date: August 29, 2023
Phase: N/A
Study type: Interventional

This study will evaluate the utility of ChatGPT in recommending treatment plans for patients with gastrointestinal cancers, using both retrospective and prospective data.

NCT ID: NCT06001372 Recruiting - Depression Clinical Trials

Ketamine-assisted Psychotherapy (KAP) for Patients With Existential Distress Associated With Non-operable GI Cancers

TREK
Start date: October 13, 2023
Phase: Early Phase 1
Study type: Interventional

The goal of this open-label clinical trial is to assess the feasibility of Ketamine-assisted psychotherapy (KAP) studies for adults with non-operable GI cancers suffering with existential distress. The main questions it aims to answer are: - Is it feasible to conduct a KAP study with this population? - What is the safety and tolerability of KAP in this population? - How prevalent is existential distress in this population? Participants will undergo KAP administered as standard of care at the HMHI Park City Ketamine-Assisted Psychotherapy Clinic and will complete health assessments over the course of the study, as well as during the therapy.

NCT ID: NCT05996458 Recruiting - Digestive Disease Clinical Trials

A Population-based, Multicenter Cohort Study of Combined Screening for Gastrointestinal Tumors

Start date: August 1, 2023
Phase:
Study type: Observational

To establish combined gastroenteroscopy screening and follow-up management for gastrointestinal tumors, explore and evaluate the feasibility and health economic benefits of combined screening for esophagus, stomach and colorectal cancer

NCT ID: NCT05995821 Recruiting - Lung Cancer Clinical Trials

Immunobiology Blood and Tissue Collection of Upper Aerodigestive Malignancies

Start date: August 25, 2016
Phase:
Study type: Observational

This research is being done to collect and store biological specimens (biospecimens) from people with cancer, regardless of tumor type, who are receiving treatments known or thought to have an effect on the immune system. The goal of this discovery and exploratory study is to: - Understand changes in the immune system associated with various cancer treatments, in order to better design new therapies or tests to predict how these treatments might work. - Identify risk factors for those who go on to develop side effects from immunotherapy. Participants may be asked to: - Donate samples of tumor, blood, lymph nodes, white blood cells, mouth cells (buccal smears) scraped from the inside of participant's cheek, urine, saliva, or other tissue samples. - Complete questionnaires about immunotherapy side effects at baseline and with follow-up appointments. - Undergo knee x-rays. - Allow the use of demographic and clinical information.

NCT ID: NCT05993702 Not yet recruiting - Regorafenib Clinical Trials

TAS-102 in Combination With Regorafenib or Fruquintinib for Third-line and Above Advanced Colorectal Cancer

Start date: September 1, 2023
Phase:
Study type: Observational

This is a single-arm, multicentre real-world observational study of TAS-102 in combination with regorafenib or fruquintinib for third-line and above advanced colorectal cancer.

NCT ID: NCT05981235 Recruiting - Clinical trials for Gastrointestinal Tumors

Phase 1 Trial of AZD6422 in CLDN18.2+ GI Tumors

Start date: December 14, 2023
Phase: Phase 1
Study type: Interventional

This is a FTiH, Phase 1 IIT to evaluate the safety, feasibility, cellular kinetics (CK), pharmacodynamics (PD), immunogenicity, and preliminary antitumor activity of AZD6422 in adult participants with advanced or metastatic CLDN18.2+ GI tumors.